SCHEMBL5057572

SCHEMBL5057572

CC(C)COC(=O)c1ccc2c(c1)N=C(c1ccc(Cl)cn1)c1c(cc(Cl)cc1C(N)=O)S2

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 7/20 0.37
KMT2A Q03164 1/20 0.35
TP53 P04637 4/20 0.34
JMJD6 Q6NYC1 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
CNR2 P34972 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP2C9 P11712 2/20 0.33
HPGD P15428 2/20 0.33
CYP2C19 P33261 2/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 2/20 0.32
GABRA5 P31644 1/20 0.32
POLB P06746 1/20 0.32
HTT P42858 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5058769 0.88 CNR1 (0.47) CNR1KMT2ATP53SMN1; SMN2CNR2
SCHEMBL5057597 0.88 CNR1 (0.41) CNR1KMT2ATP53SMN1; SMN2CNR2
SCHEMBL5057665 0.84 CNR1 (0.51) CNR1KMT2ATP53SMN1; SMN2CNR2
SCHEMBL5064751 0.76 CNR1 (0.49) CNR1TP53CNR2ALDH1A1
SCHEMBL5054181 0.75 CNR1 (0.41) CNR1KMT2ATP53SMN1; SMN2CNR2
SCHEMBL14043747 0.74 CNR1 (0.42) CNR1KMT2ATP53SMN1; SMN2CNR2
SCHEMBL5057732 0.73 CNR1 (0.44) CNR1TP53CNR2KDM4EALDH1A1
SCHEMBL5063096 0.72 CNR1 (0.44) CNR1KMT2ATP53SMN1; SMN2CNR2
SCHEMBL5057569 0.71 CNR1 (0.63) CNR1TP53SMN1; SMN2CNR2KDM4E
SCHEMBL5064679 0.67 CNR1 (0.57) CNR1TP53SMN1; SMN2CNR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE ACADIA PHARMACEUTICALS INC. (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090805-A1 CB-1 MODULATING COMPOUNDS AND THEIR USE CNR1, CNR2, FAAH CNR1 1/4885KMT2A 3357/4885TP53 4870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.